This paper was published through Galoá and has a deposited DOI. To cite this paper, use one of the standards below:
In case you are one of the co-authors and want to register this paper in your Lattes, use the following code: doi > 10.17648/bctrims-2023-167488
If you've NEVER registered a DOI in your Lattes, check our tutorial!Case presentation: A 25-year-old woman was diagnosed with relapsing-remitting multiple sclerosis (RRMS) in 2021 and started treatment with dimethyl fumarate. In August 2022, she presented a new lesion with gadolinium enhancement in the right cerebellar peduncle, associated with gastrointestinal adverse effects of the medication. For this reason, the change to fingolimod was indicated and started 2 months later. The patient had an unintentional weight loss of 5 kg in 3 months of medication use, unrelated to dietary changes, initiation of intense and regular physical activity, and without other adverse effects of the medication. Discussion: Fingolimod is a sphingosine-1-phosphate (S1PR) receptor modulator. S1P receptors are present in various organic tissues with the potential for adverse effects such as headache, elevated liver enzymes, diarrhea, cough, flu and low back pain. S1PR are present in the ventromedial and dorsomedial hypothalamic groups including anorexigenic neurons with action on leptin-melanocortin circuits. We found reports of weight loss associated with the use of fingolimod in only three cases in the literature. A retrospective study (2022) reported an incidence of 11.4% of significant weight loss, defined as a loss of 4.5 kg or 5% of body weight after initiation of fingolimod, suggesting that this adverse effect may be more frequent than previously observed. Final comments: Dietary guidelines as well as evaluation of changes in appetite and weight, should be observed in patients after initiation of treatment with fingolimod. In addition, more research is needed to clarify the effect of fingolimod on patients weight.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper